RYAAY

63.53

-0.35%↓

KNEBV.FI

53.58

-0.11%↓

MTX1

376.6

-0.63%↓

WRT1V.FI

24.37

+1.58%↑

BVI

26.84

+0.9%↑

RYAAY

63.53

-0.35%↓

KNEBV.FI

53.58

-0.11%↓

MTX1

376.6

-0.63%↓

WRT1V.FI

24.37

+1.58%↑

BVI

26.84

+0.9%↑

RYAAY

63.53

-0.35%↓

KNEBV.FI

53.58

-0.11%↓

MTX1

376.6

-0.63%↓

WRT1V.FI

24.37

+1.58%↑

BVI

26.84

+0.9%↑

RYAAY

63.53

-0.35%↓

KNEBV.FI

53.58

-0.11%↓

MTX1

376.6

-0.63%↓

WRT1V.FI

24.37

+1.58%↑

BVI

26.84

+0.9%↑

RYAAY

63.53

-0.35%↓

KNEBV.FI

53.58

-0.11%↓

MTX1

376.6

-0.63%↓

WRT1V.FI

24.37

+1.58%↑

BVI

26.84

+0.9%↑

Search

mutares AG

Închisă

27.1 0.18

Rezumat

Modificarea prețului

24h

Curent

Minim

25.85

Maxim

27.7

Indicatori cheie

By Trading Economics

Venit

-250M

Vânzări

2.7B

Randament dividend

6.47

Marjă de profit

-9.33

Angajați

29,000

EBITDA

-212M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+62.07% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

6.47%

2.27%

Următoarele câștiguri

12 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

690M

Deschiderea anterioară

26.92

Închiderea anterioară

27.1

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

mutares AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 21:42 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug. 2025, 21:21 UTC

Câștiguri
Principalele dinamici ale pieței

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug. 2025, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug. 2025, 21:30 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 21:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug. 2025, 21:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss $938M >RIG

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug. 2025, 20:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug. 2025, 20:15 UTC

Câștiguri

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug. 2025, 20:13 UTC

Câștiguri

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug. 2025, 20:09 UTC

Câștiguri

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug. 2025, 20:06 UTC

Câștiguri

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparație

Modificare preț

mutares AG Așteptări

Obiectiv de preț

By TipRanks

62.07% sus

Prognoză pe 12 luni

Medie 47 EUR  62.07%

Maxim 47 EUR

Minim 47 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentrumutares AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

32.95 / 35.05Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre mutares AG

Mutares SE & Co. KGaA is a private equity firm specializing in investments in secondary direct, special situations, bridge financing, recapitalization, distressed/vulture, management succession, reorganization, carve-outs, turnarounds, spin-offs and re-funding. It also considers co-investments. The firm typically acquires small and medium-sized companies. It also focuses on platform and add-on acquisitions. The firm makes investments in automotive and mobility, wood and paper, construction and infrastructure, engineering, consumer goods and services, technology, commercial repair services, automobiles and components, retail and food, healthcare equipment and services, and materials including containers and packaging. The firm primarily invests in companies with established market positions and whose focus of activity is on Europe, North America and Asia. It considers acquiring companies that have revenues between "100 million ($107.33 million) and "750 million ($804.94 million) with an EBITDA up to "5 million ($5.37 million). It prefers to acquire a controlling and majority stake in its portfolio companies. It typically makes long term investments with a holding period between three and five years. The firm prefers to invest from its personal capital and from balance sheet investments. Mutares SE & Co. KGaA was founded in February 2008 and is based in Munich, Germany, with additional offices in across Europe and Asia.